{
  "id": "5a871a6861bb38fb24000009",
  "type": "factoid",
  "question": "What disease is the ALK tyrosine kinase associated with?",
  "ideal_answer": "The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, and many kinds of ALK fusion genes have been found in a variety of carcinomas",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28007627",
    "http://www.ncbi.nlm.nih.gov/pubmed/25870797",
    "http://www.ncbi.nlm.nih.gov/pubmed/20979469",
    "http://www.ncbi.nlm.nih.gov/pubmed/21213368",
    "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
    "http://www.ncbi.nlm.nih.gov/pubmed/27179218",
    "http://www.ncbi.nlm.nih.gov/pubmed/27468968",
    "http://www.ncbi.nlm.nih.gov/pubmed/22084642",
    "http://www.ncbi.nlm.nih.gov/pubmed/11561161",
    "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
    "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
    "http://www.ncbi.nlm.nih.gov/pubmed/26811689",
    "http://www.ncbi.nlm.nih.gov/pubmed/25727400",
    "http://www.ncbi.nlm.nih.gov/pubmed/27892978",
    "http://www.ncbi.nlm.nih.gov/pubmed/21613408",
    "http://www.ncbi.nlm.nih.gov/pubmed/22184391",
    "http://www.ncbi.nlm.nih.gov/pubmed/26395848",
    "http://www.ncbi.nlm.nih.gov/pubmed/22681779",
    "http://www.ncbi.nlm.nih.gov/pubmed/21205076",
    "http://www.ncbi.nlm.nih.gov/pubmed/23104988",
    "http://www.ncbi.nlm.nih.gov/pubmed/25601484",
    "http://www.ncbi.nlm.nih.gov/pubmed/18923525",
    "http://www.ncbi.nlm.nih.gov/pubmed/20961208",
    "http://www.ncbi.nlm.nih.gov/pubmed/26076736",
    "http://www.ncbi.nlm.nih.gov/pubmed/17611412",
    "http://www.ncbi.nlm.nih.gov/pubmed/18070884",
    "http://www.ncbi.nlm.nih.gov/pubmed/26503946",
    "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
    "http://www.ncbi.nlm.nih.gov/pubmed/27899405",
    "http://www.ncbi.nlm.nih.gov/pubmed/27836576",
    "http://www.ncbi.nlm.nih.gov/pubmed/25979929",
    "http://www.ncbi.nlm.nih.gov/pubmed/23499906",
    "http://www.ncbi.nlm.nih.gov/pubmed/25759656",
    "http://www.ncbi.nlm.nih.gov/pubmed/27646667",
    "http://www.ncbi.nlm.nih.gov/pubmed/21829174",
    "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
    "http://www.ncbi.nlm.nih.gov/pubmed/21288922",
    "http://www.ncbi.nlm.nih.gov/pubmed/22998583"
  ],
  "snippets": [
    {
      "text": "ALK positive anaplastic large cell lymphoma is a T-cell lymphoma usually occurring in children and young adults. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468968",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " A 62-year-old Caucasian non-smoking woman was diagnosed with cT4N0M0\u00a0lung adenocarcinoma. Initial biopsy showed EGFR mutation and ALK rearrangement",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27646667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Significant prognostic factors included the original 4 factors used in the DS-GPA index plus 2 new factors: EGFR and ALK alterations in patients with adenocarcinoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27892978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "investigational ALK inhibitor brigatinib is active in patients with ALK-rearranged non-small cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27899405",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, initially identified through the analysis of a specific translocation associated with a rare subtype of non-Hodgkin's lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21205076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently it was demonstrated that ALK is frequently mutated in sporadic cases with advanced neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21205076",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK) is an important molecular target in neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although tyrosine kinase inhibitors abrogating ALK activity are currently in clinical use for the treatment of ALK-positive (ALK(+)) disease, monotherapy with ALK tyrosine kinase inhibitors may not be an adequate solution for ALK(+) neuroblastoma patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25351247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613408",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20979469",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The ALK gene is silent in adult tissues except for restricted sites within the nervous system (consequently, patients with ALK-positive lymphoma produce antibodies to the ALK protein) but is expressed in some neuroblastomas and rhabdomyosarcomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11561161",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25407901",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY The ALK protein functions as a transmembrane receptor tyrosine kinase; rearrangements of the ALK gene are associated with the development of NSCLC with adenocarcinoma histology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK) rearrangement lung cancer responds to ALK tyrosine kinase inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26811689",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, has been initially identified through its involvement in chromosomal translocations associated with anaplastic large cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22998583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements can derive significant clinical benefit from ALK tyrosine kinase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870797",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two ALK tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, are currently approved in Europe for use in ALK-positive NSCLC and several others are in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of patients with cancer that is ALK-positive.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27573755",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Genetic rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) gene occur in non-small cell lung cancer (NSCLC), anaplastic large cell lymphomoas, inflammatory myofibroblastic tumors, and other cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>INTRODUCTION</b>: NSCLC with de novo anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements and EGFR or KRAS mutations co-occur very rarely.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28007627",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ALK (anaplastic lymphoma kinase) is a transmembrane receptor tyrosine kinase, initially discovered as part of the NPM-ALK fusion protein, resulting from a chromosomal rearrangement frequently associated with anaplastic large cell lymphomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17611412",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is sensitive to treatment with an ALK-tyrosine kinase inhibitor (-TKI).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26395848",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25979929",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematological tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25727400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "patients with ALK-positive non-small-cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759656",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rearrangements of the anaplastic lymphoma kinase (ALK) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (NSCLCs) in 2007.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26076736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The anaplastic lymphoma kinase (ALK) gene rearrangement identifies a population of NSCLCs in whom dysregulation of ALK-tyrosine kinase (-TK) leads to uncontrolled proliferation of cancer cells,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601484",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ALK has been identified as a major neuroblastoma predisposition gene and activating mutations have been identified in a subset of sporadic neuroblastoma tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23499906",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we report the detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase, in 8% of primary neuroblastomas. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rearrangements in ALK gene and EML4 gene were first described in 2007. This genomic aberration is found in about 2%-8% of non-small-cell lung cancer (NSCLC) patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27217763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) is a T cell lymphoma defined by the presence of chromosomal translocations involving the ALK tyrosine kinase gene. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22681779",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Renal Medullary Carcinoma (RMC) is an aggressive malignancy that affects young black individuals with sickle cell trait. No effective treatment is available, resulting in an ominous clinical course, with overall survival averaging less than four months. We report rearrangement of the ALK receptor tyrosine kinase in a pediatric case of RMC harboring a t(2;10)(p23;q22) translocation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21213368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Aberrant ALK activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, systemic histiocytosis and NSCLC or through mutations in the full length protein in hereditary familial neuroblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20961208",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NPM/ALK is an oncogenic fusion protein expressed in approximately 50% of anaplastic large cell lymphoma cases. It derives from the t(2;5)(p23;q35) chromosomal translocation that fuses the catalytic domain of the tyrosine kinase, anaplastic lymphoma kinase (ALK), with the dimerization domain of the ubiquitously expressed nucleophosmin (NPM) protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18070884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rearrangements involving the ALK gene were identified in a variety of cancers,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27179218",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "genetic alterations are mutations in the kinase domain of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), which have been found in both somatic and familial neuroblastom",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein expression and underlying genetic aberrations in rhabdomyosarcoma (RMS), with special attention to clinical and prognostic implications",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22184391",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anaplastic lymphoma receptor tyrosine kinase gene (ALK) fusion is a distinct molecular subclassification of NSCLC that is targeted by anaplastic lymphoma kinase (ALK) inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27836576",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of translocations involving the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26503946",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (NB)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21829174",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "cancer"
}